Evogene Ltd. has announced a collaboration with Systasy Bioscience GmbH and LMU University Hospital Munich to develop novel therapies for neutrophil-derived inflammatory diseases, such as inflammatory bowel disease $(IBD)$. Supported by a pan-European EUREKA grant and involving the Weizmann Institute of Science, the partnership will combine Evogene’s AI-driven ChemPass AI™ platform for small molecule drug discovery, Systasy’s DNA barcoding technology for high-throughput pathway profiling, and LMU’s expertise in stem cell biology and precision diagnostics. The consortium aims to accelerate drug discovery and advance innovative therapies with significant clinical and commercial potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN85734) on February 11, 2026, and is solely responsible for the information contained therein.